text: <unk>  is a cholinesterase inhibitor that is FDA approved for the treatment of myasthenia gravis.   Common adverse reactions include diaphoresis, diarrhea, excessive salivation, increased peristalsis, nausea and vomiting, stomach cramps, muscle fasciculation, asthenia, miosis and excessive bronchial secretion.
option_0: Pyridostigmine
option_1: Physostigmine
option_2: Neostigmine
option_3: Neostigmine methylsulfate
option_4: Suxamethonium chloride
option_5: Thiocarboxime
option_6: Atropine 
option_7: Fomepizole